scispace - formally typeset
P

Peter Lichter

Researcher at German Cancer Research Center

Publications -  668
Citations -  89224

Peter Lichter is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Gene & Comparative genomic hybridization. The author has an hindex of 132, co-authored 623 publications receiving 78155 citations. Previous affiliations of Peter Lichter include Netherlands Cancer Institute & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov, +84 more
- 22 Aug 2013 - 
TL;DR: It is shown that hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types, and this results reveal the diversity of mutational processes underlying the development of cancer.
Journal ArticleDOI

A mammalian microRNA expression atlas based on small RNA library sequencing.

TL;DR: A relatively small set of miRNAs, many of which are ubiquitously expressed, account for most of the differences in miRNA profiles between cell lineages and tissues.
Journal ArticleDOI

Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

Jeremy Schwartzentruber, +66 more
- 09 Feb 2012 - 
TL;DR: The presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles, suggesting that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Journal ArticleDOI

International network of cancer genome projects

Thomas J. Hudson, +273 more
TL;DR: Systematic studies of more than 25,000 cancer genomes will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.